RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
Small cell lung cancer (SCLC) is an aggressive cancer that represents ~15% of all lung cancers. Currently there are no targeted therapies to treat SCLC. Our genomic analysis of a metastatic SCLC cohort identified recurrent RICTOR amplification. Here, we examine the translational potential of this ob...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351607/ https://www.ncbi.nlm.nih.gov/pubmed/27863413 http://dx.doi.org/10.18632/oncotarget.13362 |